Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

Model scores of the 29,894 trials active now.

Model score 35% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapyamlcellleukemiato determine
  Phrases that lowered it: participantssafety oflaboratorystem cellsdiabetes
• Sponsor's past termination rate: 17.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 4 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 39 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, dermatology: No (lowers risk) · Disease area
• Sponsor's past trials: 40 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission NCT00963521 · started 2008 · scored riskier than 84% of active trials completed
• DC Vaccination for Postremission Therapy in AML NCT01734304 · started 2013 · scored riskier than 92% of active trials completed
• DC Vaccination for Post-remission Therapy in AML NCT02405338 · started 2015 · scored riskier than 58% of active trials completed
• Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation NCT00809250 · started 2008 · scored riskier than 94% of active trials completed
• Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia NCT01373515 · started 2011 · scored riskier than 70% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.